 "Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites")
New Delhi: Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur.
The US Food and Drug Administration (USFDA) issues an EIR to a company when an inspection is satisfactorily closed.
The health regulator had inspected the company’s Nagpur manufacturing facility between 6 January and 10 January, 2020, Lupin Ltd said in a statement.
Advertisement
“We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites,” Lupin Managing Director Nilesh Gupta said.
 "India and the problems with Chinese manufacturing overcapacity")
 "'Meow Meow' worth Rs 3,000 crore seized in Pune, Delhi: What is this drug?")
 "This Week in Explainers: Will recession in UK, Japan hit daily living?")
 "FirstUp: Nitish Kumar to seek trust vote, RLD to formally join NDA… The big stories today")
 "India and the problems with Chinese manufacturing overcapacity")
 "'Meow Meow' worth Rs 3,000 crore seized in Pune, Delhi: What is this drug?")
 "This Week in Explainers: Will recession in UK, Japan hit daily living?")
 "FirstUp: Nitish Kumar to seek trust vote, RLD to formally join NDA… The big stories today")